Skip to content

Oral Antidiabetic Agents in Pregnancy

Oral Antidiabetic Agents on Gestational Diabetes: Modulating Effect on Fetal Growth - a Clinical Randomized Trial

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02091336
Enrollment
80
Registered
2014-03-19
Start date
2014-01-31
Completion date
2016-12-31
Last updated
2014-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes

Keywords

gestational diabetes, metformin, glyburide, fetal growth, capillar glucose

Brief summary

The aim of this study is to determine the efficacy of oral treatment with glyburide and metformin controlling excessive fetal growth in women with gestational diabetes, using insulin as a ransom on no response to oral treatment . It is randomized with women who seek care at the Outpatient Diabetes in Pregnancy in our hospital trial Eligible women between 18 - 45anos diagnosed with gestational diabetes , according to the WHO criteria , ratified the public network for prenatal care at the Clinic for Diabetes and Pregnancy HCPA . Women with singleton pregnancy and gestational age not exceeding 30 weeks at the time of enrollment. Pregnant women with indication for pharmacological treatment will be invited to randomization to use of oral , glyburide or metformin antidiabetic . At regular intervals of 2 - 3 weeks fetal growth will be measured with obstetric ultrasonography , until birth. The primary outcomes will be : ( 1 ) weight and gestational age at birth and the index of large for gestational age fetuses ( ≥ 90th percentile for gestational age ) ( 2 ) the use of insulin to achieve glycemic targets according to fetal growth , as an indirect measure of the inefficiency of oral medications .

Detailed description

The procedures for monitoring metabolic and obstetrical control , assessments of fetal well -being and indications for interruption are usually adopted in the Outpatient Diabetes and Pregnancy of the institution. \- Patients will be followed since their first appointment in our hospital, around the 20th week of pregnancy- until 8 weeks after labor and delivery. That being said, patients will be followed by an average of 28 weeks.

Interventions

DRUGMetformin

patients treatment

DRUGGlyburide

patients treatment

Sponsors

Hospital de Clinicas de Porto Alegre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Eligible women between 18-45 years diagnosed with gestational diabetes, according to the WHO criteria (19), ratified the public network for prenatal care at the Clinic for Diabetes and Pregnancy. * Women with singleton pregnancy and gestational age not exceeding 30 weeks at the time of enrollment, calculated from ultrasound (U.S.) Obstetric performed before the 20th week of pregnancy will be enrolled.

Exclusion criteria

* Women who present enrollment in the diagnosis of chronic hypertension, heart disease or chronic lung disease intrauterine restricted or preterm labor, growth, or even chronic diarrhea will be excluded

Design outcomes

Primary

MeasureTime frameDescription
fetal growthup to 9 monthsfetal growth will be assessed every 3 weeks by obstetric ultrasound during pregnancy until delivery

Secondary

MeasureTime frameDescription
insulin requirements to achieve glucose targetsup to 9 monthsevery week patients will have one whole day in the hospital to monitor capillar glucose levels

Other

MeasureTime frameDescription
neonatal 5th minute apgar5 minutes after birth
neonatal hypoglycaemia and respiratory distress48 hours after birth
hypoglycaemiaup to 9 monthsmedications will be suspended if patients present with repeated hypoglycaemia
need of c sectionday of birth
neonatal need of intensive care48 hours after birth
maternal weight gainup to 9 months

Countries

Brazil

Contacts

Primary ContactMaria Lucia R Oppermann, PhD
maluopp@gmail.com55 51 33598117
Backup ContactVanessa K Genro, PhD
vanessagenro@gmail.com55 51 81313734

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026